Kedrion S.p.A.
Clinical trials sponsored by Kedrion S.p.A., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New IVIg therapy aims to boost platelets in chronic ITP patients Results expected Dec 2026 (estimated)
- New antibody therapy aims to shield kids with rare immune disease from deadly infections Results expected Dec 2026 (estimated)
-
New hope for rare bleeding disorder: coagadex trial targets AL amyloidosis
Disease control CancelledThis phase 3 study tests Coagadex, a human clotting factor X, in 15 adults with acquired factor X deficiency caused by AL amyloidosis. The goal is to see if it safely stops active bleeding and helps manage bleeding during surgery. Participants receive the drug on demand for bleed…
Phase 3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New antibody therapy aims to shield kids with rare immune disease from deadly infections
Disease control OngoingThis study tests a medicine called Kedrion IVIG 10% in 30 children with primary immunodeficiency, a condition where the immune system doesn't work properly. The treatment is made from donated antibodies and is given through a vein to help prevent serious bacterial infections. Res…
Phase 3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC